Entries by Michael Kuhrt

BioFlo 320: Moving from R&D to commercial manufacturing

Precise parameter control is the foundation for efficient bioprocessing and scale-up. However, identifying the ideal scale-up strategy can be a work-intensive and time-consuming task. Here, the BioFlo 320 bioprocess controller with its innovative Scale Up Assist and other features can help you simplifying your cell culture process and scale up to working volumes of up to 40 L.

,

ADC Applications Beyond Oncology

Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.

,

Fueling innovation with accessible mRNA products

Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing lead times, this partnership will support early-phase researchers and established commercial clients with cutting-edge mRNA products.

Next European Biotechnology Guide 2026

The “16th European Biotechnology Science & Industry Guide 2026” – the handbook will present the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.

Kinase inhibitors: Promising therapeutics for neurodegenerative diseases

Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.

BioNsight® cloud: Effortless from data to insights

We are witnessing a significant industrial transformation driven by the adoption of digital tools to manage increasing data volumes and automation to streamline workflows. However, inefficiencies in process development and data management continue to pose major challenges. These challenges are magnified by the complexities of scaling biologics production and ensuring consistency across global teams. Digital tools present an opportunity to improve efficiency and enable remote monitoring of your bioreactor cultures. Introducing BioNsight cloud, a true cloud-based software solution for bioprocess monitoring and analysis. It is fully integrated into the Eppendorf bioprocess control software DASware® control 6 and also features DataHowLab, an innovative AI-enabled analytics solution to save time and resources during process development.